Linden Thomas Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Linden Thomas Advisory Services's NBIX Position: Q3 2026 in Review
Linden Thomas Advisory Services reduced its Neurocrine Biosciences (NBIX) stake by 0.79% in Q3 2026, selling an estimated $23.8K and leaving 18,528 shares worth $2.63M. The position accounts for 0.21% of the portfolio, ranked #151.
Linden Thomas Advisory Services first reported a position in NBIX in Q4 2022 and has held it in 16 quarters since. The position peaked at $3.15M in Q2 2026. 766 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Linden Thomas Advisory Services held 18,528 shares of Neurocrine Biosciences worth $2.63M as of Q3 2026.
- Linden Thomas Advisory Services sold 148 Neurocrine Biosciences shares in Q3 2026, an estimated $23.8K.
- Neurocrine Biosciences made up 0.21% of Linden Thomas Advisory Services's portfolio in Q3 2026, its #151 holding.
- Linden Thomas Advisory Services first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 16 quarters since.
- Linden Thomas Advisory Services's Neurocrine Biosciences position peaked at $3.15M in Q2 2026.
- 766 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Linden Thomas Advisory Services's 13F filing for Q3 2026, filed 19 Oct 2026.